July 27, 2009 -- PROLOR Biotech, Inc. (OTCBB: PBTH) formerly Modigene Inc., announced that it has entered into an evaluation and option agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science. Under the terms of the evaluation and option agreement, PROLOR may obtain from Yeda a license to develop a number of peptide drug candidates, including an anti obesity peptide, utilizing a delivery technology developed at the Weizmann Institute. The Weizmann Institute of Science is a world-renowned center of natural and exact sciences research and higher learning based in Rehovot, Israel... [PDF] PROLOR Biotech's Press Release -
Tuesday, May 11, 2010
PROLOR Biotech : LICENSE OPTION FROM YEDA FOR DEVELOPMENT OF LONG-ACTING ANTI-OBESITY DRUG
July 27, 2009 -- PROLOR Biotech, Inc. (OTCBB: PBTH) formerly Modigene Inc., announced that it has entered into an evaluation and option agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science. Under the terms of the evaluation and option agreement, PROLOR may obtain from Yeda a license to develop a number of peptide drug candidates, including an anti obesity peptide, utilizing a delivery technology developed at the Weizmann Institute. The Weizmann Institute of Science is a world-renowned center of natural and exact sciences research and higher learning based in Rehovot, Israel... [PDF] PROLOR Biotech's Press Release -
